Morgan Stanley analyst David Lewis maintained a Buy rating on Abbott Labs (ABT) today and set a price target of $82. The company’s shares closed yesterday at $74.27, close to its 52-week high of $74.92.
According to TipRanks.com, Lewis is a 5-star analyst with an average return of 13.2% and a 71.7% success rate. Lewis covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, Zimmer Biomet Holdings, and Baxter International.
Abbott Labs has an analyst consensus of Strong Buy, with a price target consensus of $79.50, which is a 7.0% upside from current levels. In a report issued on November 27, J.P. Morgan also maintained a Buy rating on the stock with a $81 price target.
The company has a one-year high of $74.92 and a one-year low of $54.32. Currently, Abbott Labs has an average volume of 6.69M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.